Genelux Corporation (GNLX)

Genelux will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -15.58M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About GNLX

Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity. We expect to be in the process of obtaining Institutional Review Board approvals and negotiating clinical trial agreements to begin enrollment for our Phase 3 regi... [Read more...]

Industry Health Care
Founded 2001
CEO Thomas Zindrick, J.D.
Employees 14
Stock Exchange NASDAQ
Ticker Symbol GNLX
Full Company Profile

Financial Performance

Financial Statements


Solid tumor biotech Genelux files for a $30 million IPO

Genelux, a Phase 2 biotech developing oncolytic viral immunotherapies for solid tumors, filed on Friday with the SEC to raise up to $30 million in an initial public offering.

Genelux IPO Registration Document (S-1)

Genelux has filed to go public with an IPO on the NASDAQ.